Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Date:2/24/2009

AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008.

    Highlights

    - Extra clinical trial in LPL deficiency causes a delay of the announced
      filing date for lead product GlyberaTM which is now expected H2 2009
    - Positive clinical data on GlyberaTM
    - CEO Ronald Lorijn resigned for personal reasons
    - Start of clinical multicenter Hemophilia B trial in 2009
    - Start development of treatments for Duchenne Muscular Dystrophy and
      Parkinson's disease
    - Scale up of unique and proprietary production platform to fully support
      worldwide commercial supply for current products
    - Independent supervisory board with three new members bringing extensive
      knowledge and experience.
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 34.2 million at December 31, 2008

Results comparison

AMT's operating loss increased to EUR 18.8 million for 2008, from EUR 14.7 million for 2007. The difference is primarily due to the increase of research & development costs to EUR 13.1 million, from EUR 9.8 million in 2007. This increase is particularly related to the development work on the company's lead product, GlyberaTM, increased staffing for this and other programs and an increase in research collaborations. General and administrative costs increased to EUR 5.9 million, from EUR 5.0 million in 2007, primarily as a result of increased employee costs and increased advisor's fees. The net loss for 2008 was EUR 16.9 million, as compared to a net loss of EUR 14.9 million for 2007. As of December 31, 2008, AMT had cash and cash equivalents of EUR 34.2 million, compared to EUR 51.3 million at December 31, 2007. The cash burn for the year amounted to EURO 17.2 million which i
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
4. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)... April 16, 2015 According to ... involving an outside source was ranked first among ... injuries related to lifting, pushing, pulling, holding, carrying, ... direct costs. The David Round Company takes statistics ... to working hard to develop and design equipment ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... April 16, 2015  Scientists from Cleave Biosciences will ... the Horizon," at the American Association for Cancer Research ... on Sunday, April 19, 2015 from 3:15pm to ... of Biology, will present new in vivo and mechanism ... inhibitor of p97, a critical enzyme that controls various ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... ST. LOUIS, Nov. 26 Aldrich, a division of,Sigma-Aldrich ... "materials by application",Materials Science catalog. The catalog features ... Electronics, Metal & Ceramic Science,Nanomaterials, Micro/NanoElectronics and Polymer Science. ... of the latest advances,in these fields. , ...
... 26 Thomas K. Equels, President and Managing,Director of ... board of directors,for Hemispherx BioPharma, Inc. (Amex: ... and clinical development,of new drug entities for the treatment ... Equels, legal practice is devoted to ...
... Covaris Incorporated today,announced that during the summer of 2008, ... and continued another successful year throughout,2008. To accommodate ... and marketing organization as well as implementing a,50% expansion ... The Covaris business was built upon the ...
Cached Biology Technology:Aldrich(R) Releases Materials Science Catalog That Includes Products to Advance Sustainable Energy and Nanotechnology Research 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 3Covaris Installed Instrument Base Reaches 500 Units 2
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Exotic bacteria that do not rely on oxygen may have ... early atmosphere, according to a theory that UChicago researcher Albert ... volcanic crater in Siberia. He has found that bacteria ... a surprising twist that scientists must take into account as ...
... WASHINGTON, April 26, 2011 The American Chemical Society ... " Global Challenges/Chemistry Solutions " podcast series showcasing ... friendly production of a key ingredient used to make ... and accompanying website focus on a new way to ...
... Group announced today that four individuals, representing Chile, Mexico ... in Marine Conservation. The 2011 Pew Marine ... dolphin populations, measure the economic and ecological tradeoffs of ... scientific foundation for the establishment of marine protected areas ...
Cached Biology News:Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3Pew announces 2011 recipients of distinguished marine conservation fellowship 2
Request Info...
384 Cluster Tube Racks...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
... Immunogen: Partially purified chicken ... detects vitamin D receptor (VDR) from ... and fish tissues. This antibody ... glucocorticoid receptors. MA1-710 detects both ...
Biology Products: